Skip to content

HELPER Programme (Substance Misuse) - A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis (ReCAP)

HELPER Programme (Substance Misuse) - A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis (ReCAP)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN88275061
Enrollment
135
Registered
2012-08-23
Start date
2009-01-05
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychosis Mental and Behavioural Disorders

Interventions

64 patients waiting for CBT after their first episode of schizophrenia, who agree to take part, will be randomly selected either for CR or support from a Support Time and Recovery Worker. They will se

Sponsors

Lancashire Care NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meeting DSMIV criteria for schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychosis not otherwise specified using a checklist of criteria and review of case notes; and confirmation of this diagnosis using the structured clinical interview for DSMIV Axis 1 disorders 2. DSMIV diagnosis of cannabis dependance or abuse using the appropriate sections of the structured clinical interview 3. A history of cannabis use of at least 1 day per week in at least half the weeks in the 3mths prior to assessment (those who are misusing other illict substances or alcohol will not be excluded) 4. Aged 16-35 5. No significant history of organic factors implicated in the aetiology of psychotic symptoms 6. Male & female participants

Exclusion criteria

Exclusion criteria: 1. No stable accommodation (i.e. street homeless or roofless) 2. Does not possess sufficient English to reliably complete assessments 3. Not able to give informed consent

Design outcomes

Primary

MeasureTime frame
Cannabis

Secondary

MeasureTime frame
No secondary outcome measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 5, 2026